Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum(Nutrition Sciences (Belgium)), Markus Stoffel(University of Zurich), K. N. Jayaprakash(Alnylam Pharmaceuticals (United States)), Shuanping Shi(Rockefeller University), Muthusamy Jayaraman(Forma Therapeutics (United States)), Klaus Charrise(Alnylam Pharmaceuticals (United States)), Rajendra K. Pandey(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Esther Ndungo(University of Maryland, Baltimore), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Gang Wang(Harvard University), Tomoko Nakayama(Alnylam Pharmaceuticals (United States)), Victor Koteliansky(Centre National de la Recherche Scientifique), Tracy Zimmermann(Alnylam Pharmaceuticals (United States))
Cited by 975
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k